DE3855135T2 - 2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen - Google Patents

2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen

Info

Publication number: DE3855135T2
Authority: DE; Germany
Prior art keywords: compound; phosphorothioat; oligoadenylates; thioadenylyl; water
Prior art date: 1987-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE3855135T

Other languages

English (en)

Other versions

DE3855135D1 (de

Inventor

Robert Suhadolnik

Wolfgang Pfleiderer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Temple University of Commonwealth System of Higher Education

Original Assignee

Temple University of Commonwealth System of Higher Education

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-22

Filing date

1988-10-18

Publication date

1996-09-05

1988-10-18 Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education

1996-04-25 Application granted granted Critical

1996-04-25 Publication of DE3855135D1 publication Critical patent/DE3855135D1/de

1996-09-05 Publication of DE3855135T2 publication Critical patent/DE3855135T2/de

2008-10-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

DE3855135T 1987-10-22 1988-10-18 2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen Expired - Fee Related DE3855135T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/112,591 US4924624A (en)	1987-10-22	1987-10-22	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
PCT/US1988/003634 WO1989003683A1 (en)	1987-10-22	1988-10-18	2',5'-phosphorothioate oligoadenylates and antiviral uses thereof

Publications (2)

Publication Number	Publication Date
DE3855135D1 DE3855135D1 (de)	1996-04-25
DE3855135T2 true DE3855135T2 (de)	1996-09-05

Family

ID=22344763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE3855135T Expired - Fee Related DE3855135T2 (de)	1987-10-22	1988-10-18	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen
DE3856326T Expired - Fee Related DE3856326T2 (de)	1987-10-22	1988-10-18	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE3856326T Expired - Fee Related DE3856326T2 (de)	1987-10-22	1988-10-18	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen

Country Status (8)

Country	Link
US (3)	US4924624A (de)
EP (2)	EP0694559B1 (de)
JP (1)	JP2733777B2 (de)
AT (2)	ATE135579T1 (de)
AU (1)	AU2628088A (de)
CA (1)	CA1339953C (de)
DE (2)	DE3855135T2 (de)
WO (1)	WO1989003683A1 (de)

Families Citing this family (838)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5550111A (en) *	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5643889A (en) *	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JP2976436B2 (ja) *	1988-04-27	1999-11-10	味の素株式会社	新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
ATE190981T1 (de) *	1989-10-24	2000-04-15	Isis Pharmaceuticals Inc	2'-modifizierte nukleotide
US5587361A (en) *	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5620963A (en) *	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5635488A (en) *	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US5470967A (en) *	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US6446032B1 (en) *	1990-09-21	2002-09-03	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
US6041910A (en) *	1997-09-22	2000-03-28	Jervis B. Webb Company	Baggage pusher device and system
GB9111967D0 (en) *	1991-06-04	1991-07-24	Erba Carlo Spa	2,5'-nucleotide analogs as antiviral agents
WO1993003733A1 (en) *	1991-08-12	1993-03-04	Basco, Ltd.	Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
US5571799A (en) *	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5654284A (en) *	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en) *	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5607923A (en) *	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5599797A (en) *	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en) *	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
JPH07504900A (ja) *	1992-03-12	1995-06-01	テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション	二重作用の２′，５′−オリゴアデニレート抗ウィルス誘導体およびその使用
US6537973B1 (en)	1992-03-16	2003-03-25	Isis Pharmaceuticals, Inc.	Oligonucleotide inhibition of protein kinase C
US20040127446A1 (en) *	1992-05-14	2004-07-01	Lawrence Blatt	Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5532130A (en) *	1993-07-20	1996-07-02	Dyad Pharmaceutical Corporation	Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US6653458B1 (en)	1993-09-03	2003-11-25	Isis Pharmaceuticals, Inc.	Modified oligonucleotides
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
US7276335B1 (en) *	1993-09-29	2007-10-02	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid function
JP3142574B2 (ja) *	1994-09-14	2001-03-07	テンプルユニバーシティ − オブザコモンウェルスシステムオブハイヤーエデュケーション	２′，５′ホスホロチオエート／ホスホジエステルオリゴアデニレートおよびその抗ウィルス用途
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5855911A (en) *	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20040171028A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US6111085A (en)	1996-09-13	2000-08-29	Isis Pharmaceuticals, Inc.	Carbamate-derivatized nucleosides and oligonucleosides
US6977244B2 (en)	1996-10-04	2005-12-20	Board Of Regents, The University Of Texas Systems	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6468991B1 (en)	1997-01-16	2002-10-22	Cyclis Pharmaceuticals, Inc.	Method of treating rhinoviral infections
US5955446A (en) *	1997-01-16	1999-09-21	Pentose Pharmaceuticals, Inc.	Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
AU7710398A (en)	1997-06-12	1998-12-30	Temple University - Of The Commonwealth System Of Higher Education	Aminoaklanoyl-linked conjugates of 2',5'-oligoadenylate and antiviral uses thereof
US6281201B1 (en)	1997-06-12	2001-08-28	Temple University- Of The Commonwealth System Of Higher Education	Base-modified derivatives of 2′,5′-oligoadenylate and antiviral uses thereof
EP1012331B1 (de)	1997-07-01	2006-03-29	Isis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO1999005160A2 (en) *	1997-07-25	1999-02-04	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US7704962B1 (en)	1997-10-03	2010-04-27	Board Of Regents, The University Of Texas System	Small oligonucleotides with anti-tumor activity
US7285288B1 (en)	1997-10-03	2007-10-23	Board Of Regents, The University Of Texas System	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
CA2329252A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for topical delivery of oligonucleotides
JP2003524586A (ja) *	1998-05-21	2003-08-19	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの非−非経口投与のための組成物と方法
US6461815B1 (en) *	1998-05-22	2002-10-08	North Carolina State University	Antibacterial agents and methods of screening for the same
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) *	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
IL142094A0 (en)	1998-09-29	2002-03-10	Gamida Cell Ltd	Methods of controlling proliferation and differentiation of stem and progenitor cells
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US7534605B2 (en) *	1999-06-08	2009-05-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
DE19940748A1 (de) *	1999-08-27	2001-03-01	Hugo Seinfeld	Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
EP2202241A3 (de) *	2000-04-13	2010-07-28	Thomas N. Wight	Therapeutische Verbindungen und Verfahren zur V3-Modulation, einer Versican-Isoform
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6656700B2 (en) *	2000-05-26	2003-12-02	Amersham Plc	Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) *	2000-05-26	2004-02-03	Amersham Plc	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020123474A1 (en) *	2000-10-04	2002-09-05	Shannon Mark E.	Human GTP-Rho binding protein2
EP2336166A1 (de)	2000-10-12	2011-06-22	University Of Rochester	Zusammensetzungen die die Proliferation von Krebszellen hemmen
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
KR20020069627A (ko) *	2001-02-27	2002-09-05	동부한농화학 주식회사	육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
ES2328796T3 (es)	2001-03-14	2009-11-18	Myriad Genetics, Inc.	Interaccion tsg101-gag y uso de la misma.
DK2000545T3 (da)	2001-06-20	2011-11-28	Genentech Inc	Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
DE10133858A1 (de)	2001-07-12	2003-02-06	Aventis Pharma Gmbh	Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US6822088B2 (en)	2001-07-17	2004-11-23	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides on solid support
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
WO2003013437A2 (en) *	2001-08-07	2003-02-20	University Of Delaware	Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) *	2001-08-07	2004-05-20	Kmiec Eric B.	Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
CA2460120A1 (en)	2001-09-18	2003-03-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
ATE516364T1 (de)	2001-10-09	2011-07-15	Isis Pharmaceuticals Inc	Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
JP2005525095A (ja)	2002-01-02	2005-08-25	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
IL152904A0 (en) *	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) *	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
AU2003230874A1 (en)	2002-04-16	2003-11-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20030199464A1 (en)	2002-04-23	2003-10-23	Silviu Itescu	Regeneration of endogenous myocardial tissue by induction of neovascularization
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
WO2003106617A2 (en) *	2002-06-12	2003-12-24	Tel Aviv Medical Center Research Development Fund	Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
WO2004013160A2 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
BR0314236A (pt)	2002-09-13	2005-08-09	Replicor Inc	Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EP1546170A4 (de) *	2002-09-20	2007-08-29	Univ Yale	Riboswitche, verfahren zu deren anwendung und zusammensetzungen, die mit riboswitchen verwendet werden
EP2272958A1 (de)	2002-09-26	2011-01-12	ISIS Pharmaceuticals, Inc.	Modulierung von der Forkheadbox O1A-Expression
AU2003304203A1 (en) *	2002-10-29	2005-01-04	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9827263B2 (en)	2002-11-05	2017-11-28	Ionis Pharmaceuticals, Inc.	2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
CA2504929C (en)	2002-11-05	2014-07-22	Charles Allerson	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
DK1569695T3 (da)	2002-11-13	2013-08-05	Genzyme Corp	Antisense-modulering af apolipoprotein-b-ekspression
JP4986109B2 (ja)	2002-11-13	2012-07-25	ジェンザイム・コーポレーション	アポリポタンパク質ｂ発現のアンチセンス調節
US20060009378A1 (en) *	2002-11-14	2006-01-12	Itshak Golan	Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
AU2003298650B2 (en)	2002-11-15	2010-03-11	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
CA2506127C (en)	2002-11-15	2013-07-09	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1624753B1 (de)	2002-11-21	2012-01-25	The University of Utah Research Foundation	Purinerge geruchsmodulation
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
AU2003299694A1 (en)	2002-12-20	2004-07-22	Qiagen Gmbh	Nucleic acid amplification
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
DK1597366T3 (da)	2003-02-11	2013-02-25	Antisense Therapeutics Ltd	Modulering af ekspression af insulin-lignende vækstfaktor receptor I
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US20040198640A1 (en) *	2003-04-02	2004-10-07	Dharmacon, Inc.	Stabilized polynucleotides for use in RNA interference
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
EP1620112A4 (de) *	2003-04-17	2007-04-25	Univ Columbia	Desmoglein 4 ist ein neues gen, das am haarwachstum beteiligt ist
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
AU2004253455B2 (en)	2003-06-03	2011-03-03	Eli Lilly And Company	Modulation of survivin expression
GB2417727B (en)	2003-06-13	2008-01-16	Alnylam Europe Ag	Double-stranded ribonucleic acid with increased effectiveness in an organism
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
EP1677822B1 (de) *	2003-09-18	2014-04-23	Isis Pharmaceuticals, Inc.	4'-thionucleoside und oligomere verbindungen
SG146682A1 (en)	2003-09-18	2008-10-30	Isis Pharmaceuticals Inc	Modulation of eif4e expression
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
CA2747871C (en)	2003-11-17	2018-04-10	Genentech, Inc.	Compositions and methods for the treatment of tumor of hematopoietic origin
AU2004296242A1 (en) *	2003-12-05	2005-06-23	Biovitrum Ab	Improved synthesis of 2-substituted adenosines
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en) *	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
EP2816351A3 (de) *	2004-01-27	2015-03-25	Compugen Ltd.	Verfahren und Systeme zur Annotation biomolekularer Sequenzen
US7842459B2 (en)	2004-01-27	2010-11-30	Compugen Ltd.	Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
AU2005230684B2 (en)	2004-04-05	2011-10-06	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
CA2562151C (en)	2004-04-30	2016-09-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a c5-modified pyrimidine
EP3225633B1 (de)	2004-05-21	2020-03-25	The UAB Research Foundation	Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP2008501335A (ja) *	2004-06-03	2008-01-24	アイシスファーマシューティカルズ、インク．	キメラギャップ化オリゴマー組成物
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
AU2005252663B2 (en) *	2004-06-03	2011-07-07	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006030442A2 (en) *	2004-09-16	2006-03-23	Gamida-Cell Ltd.	Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
DK1809303T3 (da) *	2004-09-23	2019-06-11	Arc Medical Devices Inc	Farmaceutisk sammensætning og metoder i relation til hæmning af fibrøs adhæsion eller inflammatoriske lidelser ved brug af lavsulfat-fucan
WO2006050999A2 (en) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S	Methods of reducing body fat
US7923206B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
RU2007137489A (ru)	2005-03-10	2009-04-20	Дженентек, Инк. (Us)	Способы и композиции для модуляции целостности сосудов
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en) *	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
EP2298829B1 (de)	2005-05-31	2017-09-20	École Polytechnique Fédérale de Lausanne (EPFL)	Triblock-Copolymere zur zytoplasmischen Verabreichung gen-basierter Arzneimittel
EP1904111A4 (de)	2005-06-03	2009-08-19	Univ Johns Hopkins	Zusammensetzungen und verfahren zur verringerung der microrna-expression zur behandlung von neoplasien
US8252756B2 (en)	2005-06-14	2012-08-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007007317A1 (en)	2005-07-07	2007-01-18	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Nucleic acid agents for downregulating h19, and methods of using same
US7776532B2 (en)	2005-08-11	2010-08-17	Synthetic Genomics, Inc.	Method for in vitro recombination
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
EP2338991B1 (de)	2005-08-29	2017-01-18	Regulus Therapeutics Inc.	Verfahren für MIR-122a-Modulation
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
IL172297A (en)	2005-10-03	2016-03-31	Compugen Ltd	Soluble vegfr-1 variants for the diagnosis of preeclampsia
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2392645A1 (de)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
CA2627025A1 (en)	2005-10-28	2007-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
WO2007056331A2 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
US8313901B2 (en) *	2005-12-21	2012-11-20	Yale University	Methods and compositions related to the modulation of riboswitches
EP1976567B1 (de)	2005-12-28	2020-05-13	The Scripps Research Institute	Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
EP2216339A1 (de)	2006-01-16	2010-08-11	Compugen Ltd.	Neuartiges Nukleotid und neuartige Aminosäuresequenzen und Verfahren zu deren Verwendung zur Diagnose
DE602007009487D1 (de) *	2006-01-27	2010-11-11	Isis Pharmaceutical Inc	6-modifizierte bicyclische nukleinsäureanaloga
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
US8129515B2 (en)	2006-01-27	2012-03-06	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
AU2007233109B2 (en)	2006-03-31	2010-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Eg5 gene
EP2015758B1 (de)	2006-05-05	2014-04-02	Isis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der expression von apo-b
DE102006020885A1 (de) *	2006-05-05	2007-11-08	Qiagen Gmbh	Einführung von Sequenzelementen in Nukleinsäuren
CN101490074B (zh) *	2006-05-11	2013-06-26	Isis制药公司	5’-修饰的双环核酸类似物
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
PL2194128T3 (pl)	2006-05-11	2012-12-31	Alnylam Pharmaceuticals Inc	Kompozycje i sposoby inhibicji ekspresji genu PCSK9
BRPI0712034A2 (pt)	2006-05-19	2012-01-10	Alnylam Pharmaceuticals Inc	modulação de rnai de aha e usos terapêuticos do mesmo
EP2192200B1 (de)	2006-05-22	2012-10-24	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der IKK-B-Gen-Expression
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
JP2010502752A (ja) *	2006-09-11	2010-01-28	イェールユニバーシティー	リシンリボスイッチ、リシンリボスイッチを用いた構造に基づく化合物設計、ならびにリシンリボスイッチを用いた使用のための方法および組成物
WO2008036933A2 (en)	2006-09-21	2008-03-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the hamp gene
EP2064223B1 (de)	2006-09-22	2013-04-24	Dharmacon, Inc.	Duplexoligonukleotide und Verfahren zum Gen-Silencing durch RNA-Interferenz
CA2927045A1 (en)	2006-10-03	2008-04-10	Muthiah Manoharan	Lipid containing formulations
US20100166743A1 (en)	2006-10-06	2010-07-01	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
US8999317B2 (en)	2006-11-01	2015-04-07	University Of Rochester	Methods and compositions related to the structure and function of APOBEC3G
CA2672297A1 (en) *	2006-12-11	2008-06-19	University Of Utah Research Foundation	Compositions and methods for treating pathologic angiogenesis and vascular permeability
EP2097448A4 (de)	2006-12-22	2010-07-21	Univ Utah Res Found	Verfahren für den nachweis von augenerkrankungen und leiden sowie ihre behandlung
US20100086526A1 (en) *	2007-01-16	2010-04-08	Abraham Hochberg	Nucleic acid constructs and methods for specific silencing of h19
US20100196403A1 (en) *	2007-01-29	2010-08-05	Jacob Hochman	Antibody conjugates for circumventing multi-drug resistance
AU2008212820B2 (en) *	2007-02-09	2014-01-30	Northwestern University	Particles for detecting intracellular targets
EP2471925A1 (de)	2007-03-22	2012-07-04	Yale University	Verfahren und Zusammensetzungen für Riboswitches, die das alternative Spleissen kontrollieren
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
CA2690281A1 (en)	2007-05-11	2008-11-20	The Johns Hopkins University	Biomarkers for melanoma
MX2009012647A (es) *	2007-05-29	2009-12-14	Univ Yale	Metodos y composiciones relacionadas con ribointerruptores que controlan la separacion alternativa y proceso de arn.
KR20100017905A (ko)	2007-05-29	2010-02-16	예일 유니버시티	리보스위치, 리보스위치의 사용 방법 및 리보스위치를 함유하는 조성물
EP2160464B1 (de) *	2007-05-30	2014-05-21	Northwestern University	Nukleinsäure-funktionalisierte nanopartikel für therapeutische anwendungen
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (de)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbozyklische bizyklische nukleinsäureanaloga
CA2692579C (en) *	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
EP2319926B1 (de)	2007-07-05	2016-08-31	Arrowhead Research Corporation	DSRNA zur Behandlung viraler Infektionen
CN101821277B (zh) *	2007-08-15	2014-05-07	Isis制药公司	四氢吡喃核酸类似物
US9422363B2 (en)	2007-08-28	2016-08-23	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2697957A1 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
LT2769729T (lt)	2007-09-04	2019-05-10	Compugen Ltd.	Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
JP2010539978A (ja)	2007-10-02	2010-12-24	アムジェンインコーポレイテッド	マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
JP2011502502A (ja) *	2007-11-05	2011-01-27	バルティックテクロノジーデヴェロプメント，リミテッド	核酸のハイブリッド形成における修飾塩基を含むオリゴヌクレオチドの使用
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
USRE47320E1 (en)	2007-11-20	2019-03-26	Ionis Pharmaceuticals, Inc.	Modulation of CD40 expression
US8546556B2 (en) *	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
EP2848688A1 (de)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
EP3100718B1 (de)	2008-01-02	2019-11-27	Arbutus Biopharma Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
US8530640B2 (en) *	2008-02-07	2013-09-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
CN102016036B (zh)	2008-02-11	2015-04-08	阿克赛医药公司	经修饰的RNAi多核苷酸及其用途
KR101397407B1 (ko)	2008-03-05	2014-06-19	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
US8426378B2 (en)	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
DK2982753T3 (en)	2008-04-18	2018-09-03	Baxter Int	Microsphere-based composition to prevent and / or reverse newly started autoimmune diabetes
CA2722668A1 (en) *	2008-04-29	2009-11-05	Wyeth Llc	Methods for treating inflammation
US8082730B2 (en) *	2008-05-20	2011-12-27	Caterpillar Inc.	Engine system having particulate reduction device and method
KR20110017005A (ko) *	2008-07-15	2011-02-18	에프. 호프만-라 로슈 아게	Ｔｇｆ-베타 수용체 유전자 발현 억제용 조성물 및 방법
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
EP2323667A4 (de) *	2008-08-07	2012-07-25	Isis Pharmaceuticals Inc	Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
JP5420668B2 (ja)	2008-08-25	2014-02-19	エクスカリアード・ファーマシューティカルズ，インコーポレイテッド	結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
EP2331690B1 (de)	2008-09-02	2016-01-13	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
CA2753338A1 (en)	2008-09-22	2010-03-25	Rxi Pharmaceuticals Corporation	Neutral nanotransporters
EP2356129B1 (de) *	2008-09-24	2013-04-03	Isis Pharmaceuticals, Inc.	Substituierte alpha-l-bicyclische nukleoside
WO2010036696A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
EP3109321B1 (de)	2008-09-25	2019-05-01	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
CA2740000C (en)	2008-10-09	2017-12-12	Tekmira Pharmaceuticals Corporation	Improved amino lipids and methods for the delivery of nucleic acids
WO2010045509A2 (en)	2008-10-15	2010-04-22	Isis Pharmaceuticals, Inc.	Modulation of factor 11 expression
EP3848461A1 (de)	2008-10-20	2021-07-14	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der transthyretinexpression
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CN102264374B (zh)	2008-10-24	2015-01-07	Isis制药公司	5′和2′双取代的核苷和由其制备的低聚化合物
RU2011124146A (ru) *	2008-11-17	2012-12-27	Ф.Хоффманн-Ля Рош Аг	Композиции и способы подавления экспрессии генов фактора vii
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
MX2011005429A (es)	2008-11-24	2011-06-21	Univ Northwestern	Composiciones de nanoparticulas de arn polivalentes.
WO2010061393A1 (en)	2008-11-30	2010-06-03	Compugen Ltd.	He4 variant nucleotide and amino acid sequences, and methods of use thereof
WO2010065662A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
RU2746478C2 (ru)	2008-12-04	2021-04-14	КьюРНА, Инк.	Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
EP2633854B1 (de)	2008-12-05	2015-09-16	Yeda Research And Development Co. Ltd.	miRNA-9 or miRNA-9* zur Verwendung in der Behandlung von ALS
JP5855462B2 (ja)	2008-12-10	2016-02-09	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ＧＮＡＱを標的としたｄｓＲＮＡ組成物および発現を阻害するための方法
CA2746508A1 (en)	2008-12-17	2010-07-15	Avi Biopharma, Inc.	Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2749536A1 (en) *	2009-01-08	2010-07-15	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
CA3036963A1 (en)	2009-01-29	2010-08-05	Arbutus Biopharma Corporation	Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
CN102307996A (zh) *	2009-02-03	2012-01-04	弗·哈夫曼-拉罗切有限公司	用于抑制ptp1b基因表达的组合物和方法
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
ES2658626T3 (es)	2009-02-12	2018-03-12	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
KR101682735B1 (ko)	2009-02-12	2016-12-06	큐알엔에이, 인크.	뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
US20120041051A1 (en)	2009-02-26	2012-02-16	Kevin Fitzgerald	Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
EP2403863B1 (de)	2009-03-02	2013-08-28	Alnylam Pharmaceuticals Inc.	Chemische modifikationen von nukleinsäure
JP6250263B2 (ja)	2009-03-04	2017-12-20	クルナ・インコーポレーテッド	サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
EP2406376A1 (de)	2009-03-12	2012-01-18	Alnylam Pharmaceuticals, Inc.	Lipidformulierte zusammensetzungen und verfahren zur hemmung der expression von eg5- und vegf-genen
ES2656290T3 (es)	2009-03-16	2018-02-26	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
KR20120022938A (ko)	2009-04-15	2012-03-12	노오쓰웨스턴 유니버시티	올리고뉴클레오티드 관능화된 나노입자의 전달
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
CA2760706C (en)	2009-05-05	2019-08-06	Alnylam Pharmaceuticals, Inc.	Methods of delivering oligonucleotides to immune cells
KR20220150411A (ko)	2009-05-05	2022-11-10	알닐람 파마슈티칼스 인코포레이티드	지질 조성물
JP5883782B2 (ja)	2009-05-06	2016-03-15	クルナ・インコーポレーテッド	脂質輸送代謝遺伝子に対する天然アンチセンス転写物の抑制による脂質輸送代謝遺伝子関連疾患の治療
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
KR20120069610A (ko) *	2009-05-15	2012-06-28	에프. 호프만-라 로슈 아게	글루코코르티코이드 수용체(ｇｃｒ) 유전자의 발현을 억제하는 조성물 및 방법
WO2010132665A1 (en)	2009-05-15	2010-11-18	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (ko)	2009-05-22	2017-02-08	큐알엔에이, 인크.	전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
US20100303795A1 (en) *	2009-05-27	2010-12-02	Soerensen Karina Dalsgaard	Marker of prostate cancer
CN103221541B (zh)	2009-05-28	2017-03-01	库尔纳公司	通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
PL3431076T3 (pl)	2009-06-10	2022-01-31	Arbutus Biopharma Corporation	Ulepszona formulacja lipidowa
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
WO2011005595A2 (en) *	2009-06-24	2011-01-13	Alios Biopharma, Inc.	2-5a analogs and their methods of use
US8859515B2 (en)	2009-06-24	2014-10-14	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
EP2446037B1 (de)	2009-06-26	2016-04-20	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
WO2011005861A1 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
CA2769665A1 (en)	2009-08-05	2011-02-10	Opko Curna, Llc	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
CN102482671B (zh)	2009-08-25	2017-12-01	库尔纳公司	通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
WO2011044902A1 (en)	2009-10-13	2011-04-21	Aarhus Universitet	Tff3 hypomethylation as a novel biomarker for prostate cancer
CA2777448C (en)	2009-10-14	2023-02-28	Ilan Sela	Compositions for controlling varroa mites in bees
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
WO2011050194A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US20110129832A1 (en) *	2009-10-27	2011-06-02	Swift Biosciences, Inc.	Polynucleotide Primers and Probes
CA2779099C (en)	2009-10-30	2021-08-10	Northwestern University	Templated nanoconjugates
WO2011056215A1 (en)	2009-11-03	2011-05-12	Landers James P	Versatile, visible method for detecting polymeric analytes
WO2011054939A2 (en)	2009-11-09	2011-05-12	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of kif10 genes
WO2011058555A1 (en)	2009-11-12	2011-05-19	Yeda Research And Development Co. Ltd.	A method of editing dna in a cell and constructs capable of same
JP5991922B2 (ja)	2009-11-13	2016-09-14	サレプタセラピューティクス，インコーポレイテッド	アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
US8916362B2 (en)	2009-11-23	2014-12-23	Swift Biosciences, Inc.	Devices comprising a polynucleotide to extend single stranded target molecules
TWI507524B (zh)	2009-11-30	2015-11-11	Genentech Inc	診斷及治療腫瘤之組合物及方法
WO2011084455A2 (en)	2009-12-16	2011-07-14	Opko Curna, Llc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
KR101891352B1 (ko)	2009-12-23	2018-08-24	큐알엔에이, 인크.	간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
EP2519633B1 (de)	2009-12-29	2017-10-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
JP5982288B2 (ja)	2009-12-29	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
NO2521784T3 (de)	2010-01-04	2018-05-05
EP2521785B1 (de)	2010-01-06	2022-03-09	CuRNA, Inc.	Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
US8779118B2 (en)	2010-01-11	2014-07-15	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2664866T3 (es)	2010-01-11	2018-04-23	Curna, Inc.	Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
WO2011088076A2 (en)	2010-01-12	2011-07-21	Yale University	Structured rna motifs and compounds and methods for their use
CA2786568A1 (en)	2010-01-25	2011-07-28	Curna, Inc.	Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011097407A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011095174A1 (en)	2010-02-08	2011-08-11	Aarhus Universitet	Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
JP5976548B2 (ja)	2010-02-22	2016-08-23	カッパーアールエヌエー，インコーポレイテッド	Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
SG183335A1 (en)	2010-02-23	2012-09-27	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011107100A1 (en)	2010-03-03	2011-09-09	Aarhus Universitet	Methods and compositions for regulation of herv4
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
AU2011224570B2 (en)	2010-03-08	2014-08-14	Monsanto Technology Llc	Polynucleotide molecules for gene regulation in plants
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
US9068185B2 (en)	2010-03-12	2015-06-30	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
WO2011112732A2 (en)	2010-03-12	2011-09-15	The Brigham And Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
US9193752B2 (en)	2010-03-17	2015-11-24	Isis Pharmaceuticals, Inc.	5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2550000A4 (de)	2010-03-24	2014-03-26	Advirna Inc	Selbstfreisetzende rnai-verbindungen von reduzierter grösse
CA2794189C (en)	2010-03-24	2022-01-11	Rxi Pharmaceuticals Corporation	Rna interference in dermal and fibrotic indications
CN106074591B (zh)	2010-03-24	2020-01-14	菲奥医药公司	眼部症候中的rna干扰
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
WO2011123468A1 (en)	2010-03-29	2011-10-06	Alnylam Pharmaceuticals, Inc.	Sirna therapy for transthyretin (ttr) related ocular amyloidosis
US9102938B2 (en)	2010-04-01	2015-08-11	Alnylam Pharmaceuticals, Inc.	2′ and 5′ modified monomers and oligonucleotides
WO2011127337A2 (en)	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
WO2011139702A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
EP2625186B1 (de)	2010-04-28	2016-07-27	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
SI2563920T1 (sl)	2010-04-29	2017-05-31	Ionis Pharmaceuticals, Inc.	Modulacija izražanja transtiretina
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CA3090304A1 (en)	2010-05-13	2011-11-17	Sarepta Therapeutics, Inc.	Antisense modulation of interleukins 17 and 23 signaling
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
RU2585229C2 (ru)	2010-05-26	2016-05-27	Курна, Инк.	Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
CA3102008A1 (en)	2010-06-02	2011-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en)	2010-06-08	2014-09-30	Isis Pharmaceuticals, Inc.	Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
US20130209463A1 (en)	2010-06-30	2013-08-15	Compugen Ltd.	Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
RU2611190C2 (ru)	2010-07-14	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US20130210901A1 (en)	2010-09-20	2013-08-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of treating neurodegenerative diseases
JP5974012B2 (ja)	2010-10-05	2016-08-23	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
ES2640755T3 (es)	2010-10-06	2017-11-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
EP2625292B1 (de)	2010-10-07	2018-12-05	The General Hospital Corporation	Krebsbiomarker
WO2012052872A2 (en)	2010-10-17	2012-04-26	Yeda Research And Development Co. Ltd.	Methods and compositions for the treatment of insulin-associated medical conditions
EP2851426B1 (de)	2010-10-18	2018-08-22	Arrowhead Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression von RRM2-Genen
WO2012054723A2 (en)	2010-10-22	2012-04-26	Opko Curna Llc	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
RU2611195C2 (ru)	2010-10-27	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с интерферон- связанным регулятором развития 1 (ifrd1), путем ингибирования природного антисмыслового транскрипта к ifrd1
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
GB201019043D0 (en)	2010-11-10	2010-12-22	Protea Biopharma N V	Use of 2',5'-oligoadenylate derivative compounds
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
CA2818824A1 (en)	2010-11-23	2012-05-31	Joseph Collard	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
KR101697396B1 (ko)	2011-02-02	2017-01-17	엑스칼리아드 파마슈티컬즈, 인코포레이티드	결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
EP2670404B1 (de)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin-modulatoren als modulatoren der virusproduktion
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
SG193923A1 (en)	2011-03-29	2013-11-29	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of tmprss6 gene
WO2012138453A1 (en)	2011-04-03	2012-10-11	The General Hospital Corporation	Efficient protein expression in vivo using modified rna (mod-rna)
EP2697256A1 (de)	2011-04-15	2014-02-19	Compugen Ltd.	Polypeptide und polynukleotide sowie ihre verwendung zur behandlung von immunerkrankungen und krebs
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2653247T3 (es)	2011-06-09	2018-02-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
CA3191066A1 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
CN103890000B (zh)	2011-06-21	2017-09-01	阿尔尼拉姆医药品有限公司	血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
EP4134433A1 (de)	2011-06-23	2023-02-15	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
TW202244278A (zh)	2011-06-30	2022-11-16	美商艾羅海德製藥公司	用於抑制ｂ型肝炎病毒基因表現之組合物及方法
CA2836855C (en)	2011-06-30	2020-07-14	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013019857A2 (en)	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
BR112014002737B1 (pt)	2011-08-04	2022-08-02	Yeda Research And Development Co. Ltd.	Mir-135
US9840715B1 (en)	2011-09-13	2017-12-12	Monsanto Technology Llc	Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
CA2848695A1 (en)	2011-09-13	2013-03-21	Monsanto Technology Llc	Methods and composition for weed control comprising inhibiting ppg oxidase
US10760086B2 (en)	2011-09-13	2020-09-01	Monsanto Technology Llc	Methods and compositions for weed control
EP2755466A4 (de)	2011-09-13	2015-04-15	Monsanto Technology Llc	Verfahren und zusammensetzungen zur unkrautbekämpfung
US10806146B2 (en)	2011-09-13	2020-10-20	Monsanto Technology Llc	Methods and compositions for weed control
CN103957697B (zh)	2011-09-13	2017-10-24	孟山都技术公司	用于杂草控制的方法和组合物
EP3382027A3 (de)	2011-09-13	2018-10-31	Monsanto Technology LLC	Verfahren und zusammensetzungen zur unkrautbekämpfung
US10829828B2 (en)	2011-09-13	2020-11-10	Monsanto Technology Llc	Methods and compositions for weed control
AU2012308320C1 (en)	2011-09-14	2018-08-23	Translate Bio Ma, Inc.	Multimeric oligonucleotide compounds
EP2755692B1 (de)	2011-09-14	2020-11-25	Northwestern University	Nanokonjugate zur durchquerung der blut-hirn-schranke
US9920326B1 (en)	2011-09-14	2018-03-20	Monsanto Technology Llc	Methods and compositions for increasing invertase activity in plants
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
WO2013055865A1 (en)	2011-10-11	2013-04-18	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
AU2012322618A1 (en)	2011-10-14	2014-05-29	Genentech, Inc.	Anti-HtrA1 antibodies and methods of use
FR2981650B1 (fr) *	2011-10-24	2013-12-27	Univ Paris Curie	Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement
US9145559B2 (en)	2011-10-27	2015-09-29	Yeda Research And Development Co. Ltd.	Methods of treating cancer
CA2895077A1 (en)	2011-12-12	2013-06-20	Beverly Packard	In vivo delivery of oligonucleotides
JP2015512616A (ja)	2012-02-01	2015-04-30	コンピュゲンエルティーディー．	Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
WO2013121426A1 (en)	2012-02-13	2013-08-22	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
US10034902B2 (en)	2012-02-22	2018-07-31	Exostem Biotec Ltd.	MicroRNAs for the generation of astrocytes
JP2015509366A (ja)	2012-02-22	2015-03-30	ブレインステムバイオテックリミテッド	神経幹細胞および運動ニューロンの生成
CA2866625C (en)	2012-03-13	2020-12-08	Swift Biosciences, Inc.	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
CA2867262C (en)	2012-03-15	2021-03-16	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9610362B2 (en)	2012-03-16	2017-04-04	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of DMPK
WO2013154798A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159091A2 (en)	2012-04-20	2013-10-24	Aptamir Therapeutics, Inc.	Mirna modulators of thermogenesis
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
EP2850186B1 (de)	2012-05-16	2018-12-19	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation der expression der smn-genfamilie
EP2850189B8 (de)	2012-05-16	2019-01-23	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation von genexpression
EP2850190B1 (de)	2012-05-16	2020-07-08	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation der mecp2-expression
AU2013264742B2 (en)	2012-05-24	2018-10-04	A.B. Seeds Ltd.	Compositions and methods for silencing gene expression
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
CA2880833A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
WO2014028739A1 (en)	2012-08-15	2014-02-20	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
CN104781271B (zh)	2012-08-20	2018-07-06	加利福尼亚大学董事会	具有生物可逆的基团的多核苷酸
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014062989A2 (en)	2012-10-18	2014-04-24	Monsanto Technology Llc	Methods and compositions for plant pest control
CA2890207A1 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
BR112015015976A2 (pt)	2013-01-01	2018-04-10	A. B. Seeds Ltd.	método para introduzir dsrna em sementes para modular a expressão genética
US10683505B2 (en)	2013-01-01	2020-06-16	Monsanto Technology Llc	Methods of introducing dsRNA to plant seeds for modulating gene expression
CA2898326C (en)	2013-01-18	2022-05-17	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
US10000767B2 (en)	2013-01-28	2018-06-19	Monsanto Technology Llc	Methods and compositions for plant pest control
US9701708B2 (en)	2013-01-31	2017-07-11	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
CA2900238A1 (en)	2013-02-22	2014-08-28	Sirna Therapeutics, Inc.	Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
WO2014164761A1 (en)	2013-03-13	2014-10-09	Monsanto Technology Llc	Methods and compositions for weed control
MX2015012334A (es)	2013-03-13	2016-02-05	Monsanto Technology Llc	Metodos y composiciones para el control de malezas.
PE20160046A1 (es)	2013-03-14	2016-02-14	Alnylam Pharmaceuticals Inc	COMPOSICION DE ARNi CONTRA EL COMPONENTE DE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
US20140283211A1 (en)	2013-03-14	2014-09-18	Monsanto Technology Llc	Methods and Compositions for Plant Pest Control
US10568328B2 (en)	2013-03-15	2020-02-25	Monsanto Technology Llc	Methods and compositions for weed control
EP4286517A3 (de)	2013-04-04	2024-03-13	President and Fellows of Harvard College	Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
BR112015027377B1 (pt)	2013-05-01	2023-01-10	Ionis Pharmaceuticals, Inc	Compostos oligoméricos com grupos de conjugado, composições compreendendo os referidos compostos e usos dos mesmos
SG10201913872XA (en)	2013-05-22	2020-03-30	Alnylam Pharmaceuticals Inc	SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SG11201510565TA (en)	2013-05-22	2016-01-28	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
EP3007704B1 (de)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Kombinationstherapie der akromegalie
US9850496B2 (en)	2013-07-19	2017-12-26	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
EP3030663B1 (de)	2013-07-19	2019-09-04	Monsanto Technology LLC	Zusammensetzungen und verfahren zur bekämpfung von leptinotarsa
US10894963B2 (en)	2013-07-25	2021-01-19	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
RS59991B1 (sr)	2013-08-08	2020-04-30	Scripps Research Inst	Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
US9708360B2 (en)	2013-09-30	2017-07-18	Geron Corporation	Phosphorodiamidate backbone linkage for oligonucleotides
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
US10519446B2 (en)	2013-10-04	2019-12-31	Novartis Ag	Organic compounds to treat hepatitis B virus
TW202310853A (zh)	2013-10-04	2023-03-16	美國西奈山伊坎醫學院	抑制alas1基因表現的組合物及方法
CA2925129C (en)	2013-10-04	2023-04-04	Novartis Ag	3' end caps for rnai agents for use in rna interference
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
CA2928779A1 (en)	2013-10-21	2015-04-30	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
US9758546B2 (en)	2013-10-21	2017-09-12	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3066200A1 (de)	2013-11-04	2016-09-14	Monsanto Technology LLC	Zusammensetzungen und verfahren zur bekämpfung eines befalls durch arthropoden und andere schädlinge
US10301622B2 (en)	2013-11-04	2019-05-28	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
RU2744194C2 (ru)	2013-12-02	2021-03-03	Фио Фармасьютикалс Корп	Иммунотерапия рака
CN112107693B (zh)	2013-12-03	2023-05-26	西北大学	脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
UA119253C2 (uk)	2013-12-10	2019-05-27	Біолоджикс, Інк.	Спосіб боротьби із вірусом у кліща varroa та у бджіл
CA2931090A1 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
UA121462C2 (uk)	2014-01-15	2020-06-10	Монсанто Текнолоджі Елелсі	Спосіб та композиція для боротьби із бур'янами з використанням полінуклеотидів epsps
AU2015214264B2 (en)	2014-02-04	2018-12-20	Curis, Inc.	Mutant Smoothened and methods of using the same
CA2936158C (en)	2014-02-05	2023-06-13	Yeda Research And Development Co. Ltd.	Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease
WO2015123264A1 (en)	2014-02-11	2015-08-20	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
MX2016012123A (es)	2014-03-19	2017-01-19	Ionis Pharmaceuticals Inc	Composiciones para modular la expresion de ataxina 2.
ES2926869T3 (es)	2014-04-01	2022-10-31	Biogen Ma Inc	Composiciones para modular la expresión de SOD-1
US11091770B2 (en)	2014-04-01	2021-08-17	Monsanto Technology Llc	Compositions and methods for controlling insect pests
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
CA2947270A1 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic acids targeting mdm2 or mycn
EP3137115B1 (de)	2014-05-01	2020-10-14	Ionis Pharmaceuticals, Inc.	Verfahren zur synthese von reaktiven konjugatclustern
CA2943894A1 (en)	2014-05-01	2015-11-05	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating complement factor b expression
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
EA201692370A1 (ru)	2014-05-22	2017-03-31	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
US10456445B2 (en)	2014-06-02	2019-10-29	Children's Medical Center Corporation	Methods and compositions for immunomodulation
WO2015190922A1 (en)	2014-06-10	2015-12-17	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of pompe disease
AU2015280252A1 (en)	2014-06-23	2017-01-12	Monsanto Technology Llc	Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en)	2014-06-25	2023-11-07	Monsanto Technology Llc	Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2015200697A1 (en)	2014-06-25	2015-12-30	The General Hospital Corporation	Targeting human satellite ii (hsatii)
AU2015291151B2 (en)	2014-07-15	2019-10-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Isolated polypeptides of CD44 and uses thereof
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
CA2955842A1 (en)	2014-07-29	2016-02-04	Monsanto Technology Llc	Compositions and methods for controlling insect pests
MX2017001432A (es)	2014-07-31	2017-05-09	Uab Res Found	Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
CA2958431A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016030899A1 (en)	2014-08-28	2016-03-03	Yeda Research And Development Co. Ltd.	Methods of treating amyotrophic lateral scleroses
JP2017526367A (ja)	2014-08-29	2017-09-14	チルドレンズメディカルセンターコーポレーション	癌の処置のための方法および組成物
ES2928500T3 (es)	2014-08-29	2022-11-18	Alnylam Pharmaceuticals Inc	Patisirán para su uso en el tratamiento de amiloidosis mediada por transtiretina
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10900039B2 (en)	2014-09-05	2021-01-26	Phio Pharmaceuticals Corp.	Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10556020B2 (en)	2014-09-26	2020-02-11	University Of Massachusetts	RNA-modulating agents
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en)	2014-10-30	2016-05-06	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CN113846101A (zh)	2014-11-17	2021-12-28	阿尔尼拉姆医药品有限公司	载脂蛋白C3（APOC3）iRNA组合物及其使用方法
CN107106493A (zh)	2014-11-21	2017-08-29	西北大学	球形核酸纳米颗粒缀合物的序列特异性细胞摄取
CA2969464A1 (en)	2014-12-12	2016-06-16	Tod M. Woolf	Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
PL3256589T3 (pl)	2015-01-22	2022-02-21	Monsanto Technology Llc	Kompozycje i sposoby kontrolowania leptinotarsa
JP2018506715A (ja)	2015-01-23	2018-03-08	ヴァンダービルトユニバーシティー	堅固なインターフェロメーター及びその使用方法
US10676726B2 (en)	2015-02-09	2020-06-09	Duke University	Compositions and methods for epigenome editing
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US10450342B2 (en)	2015-02-23	2019-10-22	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
WO2016135559A2 (en)	2015-02-23	2016-09-01	Crispr Therapeutics Ag	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
EP3268475B1 (de)	2015-03-11	2020-10-21	Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.	Köderoligonukleotide zur behandlung von krankheiten
BR112017020750A2 (pt)	2015-03-27	2018-06-26	Harvard College	células t modificadas e métodos de produção e utilização das mesmas
EP4218771A1 (de)	2015-03-27	2023-08-02	Yeda Research and Development Co. Ltd	Verfahren zur behandlung von motoneuronenerkrankungen
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
US10745702B2 (en)	2015-04-08	2020-08-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
EP3291677A4 (de)	2015-05-04	2019-02-13	Monsanto Technology LLC	Zusammensetzungen und verfahren zur bekämpfung eines befalls durch arthropoden und andere schädlinge
WO2016181393A1 (en)	2015-05-11	2016-11-17	Yeda Research And Development Co. Ltd.	Citrin inhibitors for the treatment of cancer
EP3302053B1 (de)	2015-06-02	2021-03-17	Monsanto Technology LLC	Zusammensetzungen und verfahren zur abgabe eines polynukleotids in eine pflanze
EP3302030A4 (de)	2015-06-03	2019-04-24	Monsanto Technology LLC	Verfahren und zusammensetzungen zum einführen von nukleinsäuren in pflanzen
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
EP3314027A4 (de)	2015-06-29	2019-07-03	Caris Science, Inc.	Therapeutische oligonukleotide
WO2017007813A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA2993652A1 (en)	2015-07-28	2017-02-02	Caris Science, Inc.	Targeted oligonucleotides
WO2017021963A1 (en)	2015-08-03	2017-02-09	Biokine Therapeutics Ltd.	Cxcr4 binding agents for treatment of diseases
EP3332009A1 (de)	2015-08-04	2018-06-13	Yeda Research and Development Co., Ltd.	Verfahren zum screening auf riboswitches und attenuatoren
CN108271387B (zh)	2015-08-07	2023-06-27	箭头药业股份有限公司	乙型肝炎病毒感染的RNAi疗法
US10889813B2 (en)	2015-09-02	2021-01-12	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
CA2998287A1 (en)	2015-09-24	2017-04-20	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP4285912A2 (de)	2015-09-25	2023-12-06	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
US11905526B2 (en)	2015-10-13	2024-02-20	Duke University	Genome engineering with Type I CRISPR systems in eukaryotic cells
CA3002744A1 (en)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017075038A1 (en)	2015-10-26	2017-05-04	Rana Therapeutics, Inc.	Nanoparticle formulations for delivery of nucleic acid complexes
US11369692B2 (en)	2015-10-28	2022-06-28	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of Duchenne Muscular Dystrophy
CA3001362C (en)	2015-10-30	2020-10-13	Genentech, Inc.	Anti-htra1 antibodies and methods of use thereof
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
CN109328231A (zh)	2015-11-06	2019-02-12	克里斯普治疗股份公司	用于治疗1a型糖原贮积病的材料和方法
EP3373939A4 (de)	2015-11-10	2019-06-26	B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University	Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP3967758A1 (de)	2015-12-01	2022-03-16	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
WO2017096395A1 (en)	2015-12-04	2017-06-08	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
EP3387127A1 (de)	2015-12-07	2018-10-17	Erasmus University Medical Center Rotterdam	Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
WO2017109757A1 (en)	2015-12-23	2017-06-29	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
EP3400300A4 (de)	2016-01-05	2019-08-07	Ionis Pharmaceuticals, Inc.	Verfahren zur reduzierung der lrrk2-expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
US20190038771A1 (en)	2016-02-02	2019-02-07	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
CN109071625A (zh)	2016-02-04	2018-12-21	柯瑞斯公司	平滑化突变体和其使用方法
EP3416689B1 (de)	2016-02-18	2023-01-18	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
WO2017161172A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
IL303936A (en)	2016-03-18	2023-08-01	Caris Science Inc	Oligonucleotide probes and their uses
EP3445388A2 (de)	2016-04-18	2019-02-27	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von hämoglobinopathien
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
IL298701B2 (en)	2016-05-25	2024-03-01	Caris Science Inc	Oligonucleotide probes and their uses
US20190256845A1 (en)	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
EP3471781A4 (de)	2016-06-17	2020-05-06	Ionis Pharmaceuticals, Inc.	Modulierung der gys1-expression
WO2017223528A1 (en)	2016-06-24	2017-12-28	The Scripps Research Institute	Novel nucleoside triphosphate transporter and uses thereof
AU2017290614C1 (en)	2016-06-29	2024-01-18	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
EP3478313B1 (de)	2016-06-29	2022-05-04	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
WO2018002812A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
EP3481856A1 (de)	2016-07-06	2019-05-15	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
AU2017292173B2 (en)	2016-07-06	2022-01-13	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
US11253601B2 (en)	2016-07-11	2022-02-22	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
KR20230088522A (ko)	2016-07-21	2023-06-19	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20170161A1 (ar)	2016-08-04	2019-01-30	Arrowhead Pharmaceuticals Inc	عوامل RNAi للعدوى بفيروس التهاب الكبد ب
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
MX2019002339A (es)	2016-09-02	2019-05-16	Dicerna Pharmaceuticals Inc	Analogos de 4'-fosfato y oligonucleotidos que los comprenden.
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
US11400161B2 (en)	2016-10-06	2022-08-02	Ionis Pharmaceuticals, Inc.	Method of conjugating oligomeric compounds
WO2018081817A2 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
AU2017378153B2 (en)	2016-12-13	2024-03-28	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
TWI790217B (zh)	2016-12-16	2023-01-21	美商阿尼拉製藥公司	使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
RU2021133626A (ru)	2017-01-23	2022-01-31	Регенерон Фармасьютикалз, Инк.	Варианты hsd17b13 и их применения
WO2018154387A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Compositions and methods for gene editing
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018165564A1 (en)	2017-03-09	2018-09-13	Ionis Pharmaceuticals, Inc.	Morpholino modified oligomeric compounds
US20180284123A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
TWI801377B (zh)	2017-04-18	2023-05-11	美商阿尼拉製藥公司	治療具有ｂ型肝炎病毒（ｈｂｖ）感染之個體之方法
CN110536694A (zh)	2017-04-20	2019-12-03	Atyr 医药公司	用于治疗肺部炎症的组合物和方法
EP3612546B1 (de)	2017-04-20	2022-07-13	Synthena AG	Modifizierte oligomere verbindungen mit tricyclischen dna-nukleosiden und verwendungen davon
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US20200384115A1 (en)	2017-04-21	2020-12-10	The Broad Institute , Inc.	Targeted delivery to beta cells
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
TWI821192B (zh)	2017-07-11	2023-11-11	美商新索思股份有限公司	非天然核苷酸之導入及其方法
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
EP3652317A1 (de)	2017-07-13	2020-05-20	Alnylam Pharmaceuticals, Inc.	Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
KR20200035092A (ko)	2017-08-03	2020-04-01	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
CA3071033A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
JP2021508333A (ja)	2017-09-19	2021-03-04	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療用組成物及び方法
MX2020004043A (es)	2017-10-17	2021-05-27	Crispr Therapeutics Ag	Composiciones y métodos para la edición génica de hemofilia a.
US20210180091A1 (en)	2017-10-26	2021-06-17	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
AU2018360697A1 (en)	2017-11-01	2020-05-14	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
EP3707155A2 (de)	2017-11-09	2020-09-16	Vertex Pharmaceuticals Incorporated	Crispr/cas-systeme für die behandlung von dmd
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
WO2019099610A1 (en)	2017-11-16	2019-05-23	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
US20190153440A1 (en)	2017-11-21	2019-05-23	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
WO2019113149A1 (en)	2017-12-05	2019-06-13	Crispr Therapeutics Ag	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
JP2021506251A (ja)	2017-12-14	2021-02-22	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
MX2020006012A (es)	2017-12-18	2020-09-14	Alnylam Pharmaceuticals Inc	Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas.
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
EP3728594A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms typ 2a
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
WO2019140330A1 (en)	2018-01-12	2019-07-18	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting transferrin
CN111902537A (zh)	2018-01-15	2020-11-06	Ionis制药公司	Dnm2表达的调节剂
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
EP3749768A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
EP3749767A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
WO2019155465A1 (en)	2018-02-08	2019-08-15	Yeda Research And Development Co. Ltd.	Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
EP3752616A1 (de)	2018-02-16	2020-12-23	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
AU2019224159A1 (en)	2018-02-26	2020-10-01	Synthorx, Inc.	IL-15 conjugates and uses thereof
EP3759127A4 (de)	2018-03-02	2022-03-30	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
TW202000199A (zh)	2018-03-02	2020-01-01	美商Ionis製藥公司	Irf4 表現之調節劑
CN112105625A (zh)	2018-03-07	2020-12-18	赛诺菲	核苷酸前体、核苷酸类似物以及含其的寡聚化合物
EP3768834A1 (de)	2018-03-19	2021-01-27	CRISPR Therapeutics AG	Neuartige rna-programmierbare endonukleasesysteme und verwendungen davon
EP3768694A4 (de)	2018-03-22	2021-12-29	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der fmr1-expression
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
JP2021520781A (ja)	2018-04-06	2021-08-26	チルドレンズメディカルセンターコーポレーションＣｈｉｌｄｒｅｎ’ＳＭｅｄｉｃａｌＣｅｎｔｅｒＣｏｒｐｏｒａｔｉｏｎ	体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
JP7275164B2 (ja)	2018-04-11	2023-05-17	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｅｚｈ２発現の調節因子
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
UY38225A (es)	2018-05-09	2019-11-29	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir de la expresión de atxn3
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
TW202016304A (zh)	2018-05-14	2020-05-01	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
EP3807411A4 (de)	2018-06-14	2022-08-03	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur verminderung der atxn3-expression
SG11202011864XA (en)	2018-06-27	2020-12-30	Ionis Pharmaceuticals Inc	Compounds and methods for reducing lrrk2 expression
BR112020025824A2 (pt)	2018-06-28	2021-03-23	Crispr Therapeutics Ag	composições e métodos para edição genômica por inserção de polinucleotídeos doadores
SG11202100077PA (en)	2018-07-25	2021-02-25	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn2 expression
JP2021533767A (ja)	2018-08-13	2021-12-09	アルナイラムファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc.	Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
EP3837367A1 (de)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
WO2020047229A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
AU2019339509A1 (en)	2018-09-14	2021-05-13	Northwestern University	Programming protein polymerization with DNA
JP2022500003A (ja)	2018-09-18	2022-01-04	アルナイラムファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc.	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
MX2021004455A (es)	2018-10-17	2021-08-11	Crispr Therapeutics Ag	Composiciones y métodos para administrar transgenes.
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
CN113646430A (zh)	2018-11-15	2021-11-12	Ionis制药公司	Irf5表达的调节剂
IL263184A (en)	2018-11-21	2020-05-31	Yarden Yosef	Method of treating cancer and compositions for same
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
HUE064532T2 (hu)	2018-12-20	2024-03-28	Vir Biotechnology Inc	Kombinációs HBV terápia
AU2019406186A1 (en)	2018-12-20	2021-07-15	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of KCNT1 related disorders
TW202043471A (zh)	2019-01-16	2020-12-01	美商健贊公司	ＳＥＲＰＩＮＣ１ｉＲＮＡ組成物及其使用方法
SG11202107399WA (en)	2019-01-31	2021-08-30	Ionis Pharmaceuticals Inc	Modulators of yap1 expression
SG11202107354WA (en)	2019-02-06	2021-08-30	Synthorx Inc	Il-2 conjugates and methods of use thereof
CA3129532A1 (en)	2019-02-15	2020-08-20	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020170240A1 (en)	2019-02-21	2020-08-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method for reduction drug-induced nephrotoxicity
JP2022523214A (ja)	2019-02-27	2022-04-21	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍａｌａｔ１発現のモジュレーター
SG11202109741VA (en)	2019-03-12	2021-10-28	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
AU2020253823A1 (en)	2019-03-29	2021-10-14	Dicerna Pharmaceuticals, Inc.	Compositions and methods for the treatment of KRAS associated diseases or disorders
TW202043251A (zh)	2019-03-29	2020-12-01	美商Ionis製藥公司	用於調節ube3a-ats 之化合物及方法
BR112021021686A2 (pt)	2019-05-03	2022-03-22	Dicerna Pharmaceuticals Inc	Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
WO2020225606A1 (en)	2019-05-08	2020-11-12	Crispr Therapeutics Ag	Crispr/cas all-in-two vector systems for treatment of dmd
CN114126628A (zh)	2019-05-13	2022-03-01	维尔生物科技有限公司	用于治疗乙型肝炎病毒(hbv)感染的组合物及方法
EP3983543A4 (de)	2019-06-14	2023-05-03	The Scripps Research Institute	Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
CA3142521A1 (en)	2019-06-17	2020-12-24	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2021021673A1 (en)	2019-07-26	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CN114555128A (zh)	2019-08-15	2022-05-27	新索思股份有限公司	采用il-2缀合物的免疫肿瘤学组合疗法
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
CA3148135A1 (en)	2019-08-23	2021-03-04	Carolina E. CAFFARO	Il-15 conjugates and uses thereof
JP2022546570A (ja)	2019-09-03	2022-11-04	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
JP2022547078A (ja)	2019-09-10	2022-11-10	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび自己免疫疾患を治療するための使用方法
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (pt)	2019-10-22	2022-07-12	Alnylam Pharmaceuticals Inc	Composições de irna de componente complementar c3 e métodos de uso das mesmas
MX2022004388A (es)	2019-11-01	2022-05-06	Alnylam Pharmaceuticals Inc	Composiciones de agentes de arni de huntingtina (htt) y metodos de uso de las mismas.
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
IL291786A (en)	2019-11-04	2022-06-01	Synthorx Inc	Interleukin 10 conjugates and their use
TW202132568A (zh)	2019-11-13	2021-09-01	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
US20230056569A1 (en)	2019-11-22	2023-02-23	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
JP2023503635A (ja)	2019-11-27	2023-01-31	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	Ｒｎａ分子を合成する方法
EP4065715A4 (de) *	2019-11-27	2024-04-10	Alnylam Pharmaceuticals Inc	Synthese von 3'-rna oligonukleotiden
EP4073251A1 (de)	2019-12-13	2022-10-19	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US20230054569A1 (en)	2019-12-18	2023-02-23	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
MX2022008738A (es)	2020-01-15	2022-09-23	Dicerna Pharmaceuticals Inc	Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos.
US20230057461A1 (en)	2020-01-27	2023-02-23	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021163066A1 (en)	2020-02-10	2021-08-19	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing vegf-a expression
MX2022010052A (es)	2020-02-18	2022-09-05	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) contra la apolipoproteina c3 (apoc3) y metodos para su uso.
PE20221913A1 (es)	2020-02-28	2022-12-23	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular smn2
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
EP4114948A1 (de)	2020-03-06	2023-01-11	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
TW202204615A (zh)	2020-03-26	2022-02-01	美商阿尼拉製藥公司	冠狀病毒ｉＲＮＡ組成物及其使用方法
WO2021202443A2 (en)	2020-03-30	2021-10-07	Alnylam Pharmaceucticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
BR112022020145A2 (pt)	2020-04-06	2023-01-03	Alnylam Pharmaceuticals Inc	Composições e métodos para silenciamento da expressão de myoc
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
TW202204617A (zh)	2020-04-07	2022-02-01	美商艾爾妮蘭製藥公司	用於靜默scn9a表現之組合物及方法
EP4143319A1 (de)	2020-04-27	2023-03-08	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
CA3181198A1 (en)	2020-04-30	2021-11-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
JP2023524065A (ja)	2020-05-01	2023-06-08	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ａｔｘｎ１を調節するための化合物及び方法
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
EP4153747A2 (de)	2020-05-22	2023-03-29	Wave Life Sciences Ltd.	Doppelsträngige oligonukleotidzusammensetzungen und zugehörige verfahren
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4161552A1 (de)	2020-06-05	2023-04-12	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von neoplasien
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
KR20230026455A (ko)	2020-06-18	2023-02-24	알닐람 파마슈티칼스 인코포레이티드	크산틴 데하이드로게나제 (XDH) iRNA 조성물 및 이의 사용 방법
BR112022026316A2 (pt)	2020-06-24	2023-03-07	Vir Biotechnology Inc	Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
TW202216203A (zh)	2020-06-25	2022-05-01	美商欣爍克斯公司	Il-2接合物及抗egfr抗體之免疫腫瘤學組合治療
KR20230029837A (ko)	2020-06-29	2023-03-03	아이오니스 파마수티컬즈, 인코포레이티드	Plp1을 조절하기 위한 화합물 및 방법
MX2023001541A (es)	2020-08-04	2023-03-08	Dicerna Pharmaceuticals Inc	Administracion sistemica de oligonucleotidos.
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4222264A1 (de)	2020-09-30	2023-08-09	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
TW202228786A (zh)	2020-10-09	2022-08-01	美商欣爍克斯公司	Il-2接合物的免疫腫瘤學療法
AU2021356693A1 (en)	2020-10-09	2023-06-15	Synthorx, Inc.	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
EP4228637A1 (de)	2020-10-15	2023-08-23	Yeda Research and Development Co. Ltd	Verfahren zur behandlung von myeloidmalignitäten
AU2021365822A1 (en)	2020-10-21	2023-06-08	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3200595A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	Coagulation factor v (f5) irna compositions and methods of use thereof
CA3201661A1 (en)	2020-11-18	2022-05-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating angiotensinogen expression
WO2022106695A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
TW202237150A (zh)	2020-12-01	2022-10-01	美商艾拉倫製藥股份有限公司	用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
JP2024501288A (ja)	2020-12-23	2024-01-11	フラッグシップパイオニアリングイノベーションズシックス，エルエルシー	修飾ｔｒｅｍの組成物及びその使用
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
BR112023015761A2 (pt)	2021-02-12	2023-11-07	Alnylam Pharmaceuticals Inc	Superóxido dismutase 1 (sod1) composições de irna e métodos de uso das mesmas para tratar ou prevenir doenças neurodegenerativas associadas a superóxido dismutase 1 (sod1)
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
WO2022182864A1 (en)	2021-02-25	2022-09-01	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods and methods of use thereof
EP4298218A1 (de)	2021-02-26	2024-01-03	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230150843A (ko)	2021-03-04	2023-10-31	알닐람 파마슈티칼스 인코포레이티드	안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 이의 사용 방법
US20220288181A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230162024A (ko)	2021-03-29	2023-11-28	알닐람 파마슈티칼스 인코포레이티드	헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
BR112023022284A2 (pt)	2021-04-26	2023-12-26	Alnylam Pharmaceuticals Inc	Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
WO2022232343A1 (en)	2021-04-29	2022-11-03	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022246023A1 (en)	2021-05-20	2022-11-24	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
TW202317762A (zh)	2021-06-02	2023-05-01	美商艾拉倫製藥股份有限公司	含有類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）的ｉＲＮＡ組成物及其使用方法
WO2022256534A1 (en)	2021-06-03	2022-12-08	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
IL308743A (en)	2021-06-04	2024-01-01	Alnylam Pharmaceuticals Inc	Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them
AR126070A1 (es)	2021-06-08	2023-09-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
BR112023023768A2 (pt)	2021-06-11	2024-02-27	Bayer Ag	Sistemas de endonucleases programáveis por rna tipo v
CA3223192A1 (en)	2021-06-18	2022-12-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
KR20240026203A (ko)	2021-06-30	2024-02-27	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
TW202333748A (zh)	2021-07-19	2023-09-01	美商艾拉倫製藥股份有限公司	用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
KR20240037293A (ko)	2021-07-23	2024-03-21	알닐람 파마슈티칼스 인코포레이티드	베타-카테닌(CTNNB1) iRNA 조성물 및 이의 사용 방법
WO2023009687A1 (en)	2021-07-29	2023-02-02	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
IL310244A (en)	2021-08-03	2024-03-01	Alnylam Pharmaceuticals Inc	Transthyretin (TTR) IRNA compositions and methods of using them
CA3228255A1 (en)	2021-08-04	2023-02-09	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing angiotensinogen (agt)
AR126771A1 (es)	2021-08-13	2023-11-15	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ARNi CONTRA EL FACTOR XII (F12) Y SUS MÉTODOS DE USO
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023076451A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023177866A1 (en)	2022-03-18	2023-09-21	Dicerna Pharmaceuticals, Inc.	Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2024026474A1 (en)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	Enqp type ii cas proteins and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2002773B (en) *	1977-08-10	1982-03-03	Brown R	Nucleotide inhibitor of protein synthesis
US4210746A (en) *	1978-08-10	1980-07-01	National Research Development Corporation	Nucleotide inhibitor of protein synthesis
US4464359A (en) *	1981-04-10	1984-08-07	Research Corporation	(2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
US4515781A (en) *	1983-02-23	1985-05-07	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	2',5'-Riboadenylate-morpholinoadenylate nucleotides
US4565696A (en) *	1983-08-03	1986-01-21	The Regents Of The University Of California	Production of immunogens by antigen conjugation to liposomes
FR2567892B1 (fr) *	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions
US4781871A (en) *	1986-09-18	1988-11-01	Liposome Technology, Inc.	High-concentration liposome processing method
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5866787A (en) *	1993-03-08	1999-02-02	Cleveland Clinic Foundation	Transgenic plants co-expressing a functional human 2-5A system

1987
- 1987-10-22 US US07/112,591 patent/US4924624A/en not_active Expired - Lifetime
1988
- 1988-10-18 AU AU26280/88A patent/AU2628088A/en not_active Abandoned
- 1988-10-18 WO PCT/US1988/003634 patent/WO1989003683A1/en active IP Right Grant
- 1988-10-18 DE DE3855135T patent/DE3855135T2/de not_active Expired - Fee Related
- 1988-10-18 EP EP95202077A patent/EP0694559B1/de not_active Expired - Lifetime
- 1988-10-18 CA CA000580426A patent/CA1339953C/en not_active Expired - Fee Related
- 1988-10-18 JP JP63509144A patent/JP2733777B2/ja not_active Expired - Fee Related
- 1988-10-18 DE DE3856326T patent/DE3856326T2/de not_active Expired - Fee Related
- 1988-10-18 EP EP88909900A patent/EP0389521B1/de not_active Expired - Lifetime
- 1988-10-18 AT AT88909900T patent/ATE135579T1/de not_active IP Right Cessation
- 1988-10-18 AT AT95202077T patent/ATE178902T1/de not_active IP Right Cessation
1992
- 1992-07-16 US US07/915,771 patent/US5405939A/en not_active Expired - Lifetime
1994
- 1994-12-02 US US08/348,419 patent/US5556840A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1989003683A1 (en)	1989-05-05
JP2733777B2 (ja)	1998-03-30
US5405939A (en)	1995-04-11
US5556840A (en)	1996-09-17
EP0389521A1 (de)	1990-10-03
AU2628088A (en)	1989-05-23
EP0694559A2 (de)	1996-01-31
ATE178902T1 (de)	1999-04-15
US4924624A (en)	1990-05-15
DE3856326T2 (de)	1999-12-02
DE3856326D1 (de)	1999-05-20
DE3855135D1 (de)	1996-04-25
EP0694559A3 (de)	1996-07-31
CA1339953C (en)	1998-07-14
EP0389521B1 (de)	1996-03-20
EP0694559B1 (de)	1999-04-14
ATE135579T1 (de)	1996-04-15
EP0389521A4 (en)	1992-02-05
JPH04500795A (ja)	1992-02-13

Legal Events

Date	Code	Title	Description
1997-04-17	8364	No opposition during term of opposition
2006-08-17	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE3855135D1 (de)	1996-04-25	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen
DE69330274D1 (de)	2001-07-05	Enantiomerisch reine beta-d-dioxolan-nukleoside
DE69025529T2 (de)	1996-10-17	Weitere antivirale Pyrimidin-Nukleosiden
DK108491A (da)	1991-06-07	Nucleosider og nucleosidanaloge samt farmaceutiske praeparater indeholdende disse forbindelser
DE68920125T2 (de)	1995-08-03	Pyrimidindion-Derivate, Verfahren zu deren Herstellung und diese enthaltende antiarrythmische Mittel.
HK1002108A1 (en)	1998-07-31	Optically active pyridonecarboxylic acid derivatives
DK232989D0 (da)	1989-05-12	Antiviralt praeparat
DK291390A (da)	1990-12-07	Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
TR199801196T2 (xx)	1998-10-21	Biyolojik aktif benzotiyazolon etanaminler.
ATE90685T1 (de)	1993-07-15	Disaccharidderivate.
NO176609C (no)	1995-05-03	Fremgangsmåte til fremstilling av et sterkt vannlöselig, stabilt, krystallinsk salt av 2',3'-dideoksyinosin, 2',3'-dideoksy-2',3'didehydrotymidin eller 2',3'dideoksy-2'-fluorinosin
FR2577553B1 (fr)	1991-06-21	Derives de l'ergoline et leurs sels formes par addition avec des acides, et leurs applications therapeutiques
DE68914809T2 (de)	1994-08-11	Antivirale Wirkstoffe.
FI812773L (fi)	1982-03-13	Foerfarande foer framstaellning av n-/4-/(2,4-diamino-6-pteridinyl)-metyl/metylamino/benzoyl/glutaminsyra
ATE101119T1 (de)	1994-02-15	Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.